- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-radiographic axial spondyloarthritis (nr-axSpA)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1303KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 141KB)
Ixekizumab – November 2021
Ixekizumab: Injection 80 mg in 1 mL single dose pre-filled pen; Taltz®
Last updated
4 March 2022